Search
Meningococcal polysaccharide vaccine group W-135
go.drugbank.com/drugs/DB13887ApprovedInvestigationalIt is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup W-135.
Mixtures: MENCEVAX ACWY 0,5 ML SC ENJEKSİYON İÇİN LİYOFİLİZE TOZ İÇEREN ÇOK DOZLU FLAKON, 50 ADET, MENACTRA 0,5 ML IM ENJEKSİYONLUK ÇÖZELTİ İÇEREN FLAKON, 5 ADETGastric intrinsic factor
go.drugbank.com/drugs/DB09349Approvedresponsive to oral iron therapy. … However, it is currently in the marketed (but unapproved) product Hematogen in combination with cyanocobalamin (synthetic Vitamin B12), ferrous fumarate, and ascorbic acid for the treatment of anemias
Mixtures: TL-IconTrovafloxacin
go.drugbank.com/drugs/DB00685ApprovedWithdrawnIt was shown to be more effective against Gram-positive bacteria than Gram-negative bacteria when compared to previous fluoroquinolones. … Due to its hepatotoxic potential, trovafloxacin was withdrawn from the market.
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme InhibitorsArimoclomol
go.drugbank.com/drugs/DB05025ApprovedArimoclomol is a hydroxylamine derivative [A264414] and a heat-shock protein-70 (HSP70) co-inducer. … [L51384] Arimoclomol was approved by the FDA on September 20, 2024, making it the first treatment for Niemann-Pick disease, type C (NPC).
Meningococcal polysaccharide vaccine group A
go.drugbank.com/drugs/DB13889ApprovedInvestigationalIt is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup A.
Mixtures: MENCEVAX ACWY 0,5 ML SC ENJEKSİYON İÇİN LİYOFİLİZE TOZ İÇEREN ÇOK DOZLU FLAKON, 50 ADET, MENACTRA 0,5 ML IM ENJEKSİYONLUK ÇÖZELTİ İÇEREN FLAKON, 5 ADETPitolisant
go.drugbank.com/drugs/DB11642ApprovedInvestigational[A32025] About 60-70% of patients with narcolepsy experience cataplexy, which is a sudden loss of muscle tone triggered by positive or negative emotions. … [A32024] The therapeutic effectiveness of pitolisant was comparable to that of [modafinil].
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP2B6 InducersCrotalus atrox antivenin
go.drugbank.com/drugs/DB13892ApprovedThe majority of people bitten are males and about 50% occur in the age group of 18 to 28 [F113]. … It is intravenously (IV) administered to prevent/limit systemic toxicity [FDA label].
16S/23S rRNA (cytidine-2'-O)-methyltransferase TlyA
go.drugbank.com/bio_entities/BE0009727TargetMycobacterium tuberculosis (strain ATCC 25618 / H37Rv)Acts as a host evasion factor, that significantly contributes to the pathogenesis of M.tuberculosis by modulating adaptive immune responses by inhibiting host-protective Th1 and Th17 cytokine responses … Catalyzes the 2'-O-methylation at nucleotides C1409 in 16S rRNA and C1920 in 23S rRNA (PubMed:16857584, PubMed:20854656). Is likely involved in ribosomal biogenesis (PubMed:21443791).
Polypeptides: 16S/23S rRNA (cytidine-2'-O)-methyltransferase TlyASynonyms: 16S rRNA (cytidine1409-2'-O)-methyltransferaseTegafur
go.drugbank.com/drugs/DB09256ApprovedInvestigationalTegafur is usually given in combination with other drugs that enhance the bioavailability of the 5-FU by blocking the enzyme responsible for its degradation, or serves to limit the toxicity of 5-FU by … When converted and bioactivated to 5-FU, the drug mediates an anticancer activity by inhibiting thymidylate synthase (TS) during the pyrimidine pathway involved in DNA synthesis. 5-FU is listed on the
Mixtures: TS-ONE CAPSULE 20, TS-ONE CAPSULE 20Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesMeningococcal polysaccharide vaccine group Y
go.drugbank.com/drugs/DB13888ApprovedInvestigationalIt is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup Y.
Mixtures: MENCEVAX ACWY 0,5 ML SC ENJEKSİYON İÇİN LİYOFİLİZE TOZ İÇEREN ÇOK DOZLU FLAKON, 50 ADET, MENACTRA 0,5 ML IM ENJEKSİYONLUK ÇÖZELTİ İÇEREN FLAKON, 5 ADET